News - UF Innovate

UF Researchers Find New Sugar Substitutes in Citrus That Could Change Food and Beverage Industry

Finding natural, non-caloric sugar substitutes is desirable but challenging. However, researchers at the University of Florida Institute of Food and Agricultural Sciences have made a breakthrough — discovering new, natural sweeteners in citrus for the first time.

New HiPerGator Simulations “Solve Mother Nature” To Address Real-World Problems

In one of the most intensive uses yet of the University of Florida’s HiPerGator supercomputer, UF engineers have faithfully reproduced the turbulence and complexity of hot air rising along a wall — a previously impossible simulation with applications in home fire safety and heating and cooling.

How Members of the UF Community Represent the Core Values

University of Florida Core Values Week strives to make the university community a premier university in the state, nation and world to look to for leadership.

UF Health Researcher Aims To Create AI Algorithm To Help Map Human Body’s Cells

Recently hired UF College of Medicine faculty member Pinaki Sarder, Ph.D., is leading a project where researchers at UF Health are developing an artificial intelligence algorithm to be used by scientists around the nation who are mapping out the entire human body at the single-cell level.

Concept Companies and Lacerta Therapeutics Form a Strategic Partnership Around Facilities Expansion and Financing

Concept Companies, a national commercial real estate developer with a specialty across multiple asset classes including science and technology, and Lacerta Therapeutics, Inc., a leader in the AAV gene therapy space, today announced a strategic collaboration providing Lacerta with access to financing to support expansion of operations and new facilities. The financing is being provided via Agility Venture Capital, the funding arm of Concept Companies.

UF Researchers Use AI To Predict New Coronavirus Variants

A new research grant led by University of Florida professors and is attempting to see if AI can help predict the next wave of coronavirus.

Lacerta and Prevail, a Wholly Owned Subsidiary of Lilly, Sign Agreement To Develop Novel AAV Capsids for CNS Disorders

Lacerta Therapeutics, a leader in the development of adeno-associated virus (AAV) technologies for the treatment of central nervous system (CNS) diseases, announced a new AAV capsid licensing and research collaboration agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The collaboration will focus on the discovery and development of novel AAV capsids for CNS diseases.

UF News